Biotech firm Genevant Sciences announced that it will collaborate with biotech startup Tome Biosciences on an in vivo gene editing treatment for a rare liver disorder.
The collaboration and nonexclusive licensing agreement will combine Basel, Switzerland-based Genevant’s proprietary lipid nanoparticle (LNP) technology with Tome’s programmable genomic integration technology to develop the gene-editing therapeutic for the undisclosed monogenic liver disorder.
In a statement, Genevant said that the terms of the agreement provide for a total deal value for Genevant of approximately $114.3 million, with additional royalties on future sales of the resulting drug. Other terms of the agreement were not disclosed.
“Successful delivery is critical to realizing the promise of next-generation gene editing approaches like Tome’s, highlighting the importance of world-class LNP technology,” Pete Lutwyche, PhD, president and CEO of Genevant said. “We are pleased to be working with Tome to bring its innovative gene editing technology to patients.”
Watertown, MA-based Tome Biosciences emerged in December with $213 million in funding; the firm acquired Replace Therapeutics at the beginning of the year.
